Total Payments
$42,247
2024 Payments
$3,306
Companies
38
Transactions
132
Medicare Patients
2,040
Medicare Billing
$436,328
Payment Breakdown by Category
Consulting$26,816 (63.5%)
Food & Beverage$8,007 (19.0%)
Other$4,875 (11.5%)
Travel$1,750 (4.1%)
Education$798.99 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $26,816 | 11 | 63.5% |
| Food and Beverage | $8,007 | 91 | 19.0% |
| Honoraria | $1,950 | 1 | 4.6% |
| Travel and Lodging | $1,750 | 8 | 4.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,725 | 1 | 4.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,200 | 1 | 2.8% |
| Education | $798.99 | 19 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $16,500 | 21 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $4,908 | 14 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $4,214 | 4 | $0 (2021) |
| Heron Therapeutics, Inc. | $1,842 | 2 | $0 (2018) |
| Janssen Biotech, Inc. | $1,828 | 11 | $0 (2024) |
| CTI BioPharma Corp. | $1,725 | 1 | $0 (2023) |
| GlaxoSmithKline, LLC. | $1,625 | 1 | $0 (2022) |
| BeiGene USA, Inc. | $1,578 | 3 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $1,200 | 1 | $0 (2020) |
| TESARO, Inc. | $1,030 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,306 | 15 | AstraZeneca Pharmaceuticals LP ($2,361) |
| 2023 | $4,436 | 11 | AstraZeneca Pharmaceuticals LP ($2,288) |
| 2022 | $17,969 | 30 | Bayer HealthCare Pharmaceuticals Inc. ($14,217) |
| 2021 | $2,818 | 9 | Karyopharm Therapeutics Inc. ($2,264) |
| 2020 | $5,571 | 7 | Bayer HealthCare Pharmaceuticals Inc. ($2,200) |
| 2019 | $2,719 | 23 | TESARO, Inc. ($1,030) |
| 2018 | $3,415 | 23 | Heron Therapeutics, Inc. ($1,842) |
| 2017 | $2,013 | 14 | Janssen Biotech, Inc. ($1,005) |
All Payment Transactions
132 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Boston Scientific Corporation | TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) (Device) | Food and Beverage | In-kind items and services | $149.93 | General |
| Category: TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)_PI | ||||||
| 12/03/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $112.65 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $130.10 | General |
| Category: Oncology | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $121.89 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $25.94 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $29.40 | General |
| Category: Oncology | ||||||
| 06/24/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $110.68 | General |
| Category: Oncology | ||||||
| 04/24/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $102.33 | General |
| Category: Oncology | ||||||
| 03/28/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $112.12 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $122.94 | General |
| Category: Oncology | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $110.53 | General |
| Category: Oncology | ||||||
| 02/08/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: Oncology | ||||||
| 02/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $115.38 | General |
| Category: Oncology | ||||||
| 01/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $116.07 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $112.51 | General |
| Category: Oncology | ||||||
| 11/13/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Hematology | ||||||
| 10/04/2023 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $116.27 | General |
| Category: Oncology | ||||||
| 09/11/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,820.00 | General |
| Category: Oncology | ||||||
| 08/24/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $105.38 | General |
| Category: Oncology | ||||||
| 08/15/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 05/08/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.80 | General |
| Category: ONCOLOGY | ||||||
| 03/21/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $125.15 | General |
| Category: Oncology | ||||||
| 03/21/2023 | Eisai Inc. | Lenvima (Drug) | Education | Cash or cash equivalent | $12.99 | General |
| Category: Oncology | ||||||
| 03/01/2023 | Genentech USA, Inc. | Lunsumio (Biological) | Food and Beverage | In-kind items and services | $149.99 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 600 | 1,071 | $442,430 | $128,171 |
| 2022 | 3 | 447 | 1,028 | $359,676 | $103,059 |
| 2021 | 5 | 502 | 1,174 | $396,197 | $116,837 |
| 2020 | 4 | 491 | 1,035 | $331,790 | $88,261 |
Total Patients
2,040
Total Services
4,308
Medicare Billing
$436,328
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 209 | 466 | $214,826 | $69,966 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 237 | 345 | $118,335 | $29,592 | 25.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 67 | 67 | $43,952 | $11,270 | 25.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 74 | $25,530 | $7,328 | 28.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 82 | $19,516 | $5,400 | 27.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $11,271 | $2,454 | 21.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 20 | $9,000 | $2,161 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 356 | 907 | $302,031 | $87,287 | 28.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 74 | 74 | $46,694 | $13,020 | 27.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 47 | $10,951 | $2,752 | 25.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 358 | 925 | $298,775 | $90,010 | 30.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 83 | 83 | $50,879 | $14,817 | 29.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 33 | 134 | $30,284 | $7,704 | 25.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $8,203 | $2,163 | 26.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 19 | $8,056 | $2,143 | 26.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 373 | 870 | $268,830 | $71,353 | 26.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 76 | 76 | $44,156 | $11,828 | 26.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 26 | 73 | $15,476 | $4,475 | 28.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 16 | 16 | $3,328 | $604.18 | 18.2% |
About Dr. Uma Gowda, MD
Dr. Uma Gowda, MD is a Hematology & Oncology healthcare provider based in Roseville, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013976570.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Uma Gowda, MD has received a total of $42,247 in payments from pharmaceutical and medical device companies, with $3,306 received in 2024. These payments were reported across 132 transactions from 38 companies. The most common payment nature is "Consulting Fee" ($26,816).
As a Medicare-enrolled provider, Gowda has provided services to 2,040 Medicare beneficiaries, totaling 4,308 services with total Medicare billing of $436,328. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Roseville, CA
- Active Since 03/22/2006
- Last Updated 08/16/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1013976570
Products in Payments
- Xofigo (Drug) $9,195
- Nubeqa (Drug) $7,221
- XPOVIO (Drug) $4,214
- CALQUENCE (Drug) $2,297
- SUSTOL (Drug) $1,842
- Vonjo (Drug) $1,725
- BLENREP (Biological) $1,625
- BRUKINSA (Drug) $1,578
- Tavalisse (Drug) $1,200
- IMBRUVICA (Drug) $1,121
- ZEJULA (Drug) $1,030
- KEYTRUDA (Biological) $431.02
- OPDIVO (Biological) $405.54
- XTANDI (Drug) $386.31
- Erleada (Drug) $301.10
- RYBREVANT (Drug) $263.59
- TECENTRIQ (Biological) $261.85
- LYNPARZA (Drug) $241.77
- ADCETRIS (Biological) $218.06
- TAGRISSO (Drug) $216.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Roseville
Jitender Jain, M.d, M.D
Hematology & Oncology — Payments: $6,964
Hematology & Oncology $6,964
Sharon Peng, M.d, M.D
Hematology & Oncology — Payments: $3,079
Hematology & Oncology $3,079
Sivakumar Reddy, Md, MD
Hematology & Oncology — Payments: $2,922
Hematology & Oncology $2,922
Sidney Crain, Md, MD
Hematology & Oncology — Payments: $2,874
Hematology & Oncology $2,874
Kristie Bobolis, M.d, M.D
Hematology & Oncology — Payments: $990.93
Hematology & Oncology $990.93
Li Hu, Md, MD
Hematology & Oncology — Payments: $296.72
Hematology & Oncology $296.72